WALTHAM, Mass. --(BUSINESS WIRE)-- In recognition of Pain Awareness Month this September, NeuroMetrix, Inc. (Nasdaq: NURO) is partnering with the U.S. Pain Foundation , a nonprofit organization dedicated to serving those who live with pain conditions and their providers, to raise awareness of the

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the upcoming PAINWeek national conference to be held in Las Vegas, NV, September 5-9. Both studies leveraged the Quell ® Health Cloud, which connects with the Quell

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq:NURO) today announced it will be a presenting company at the 19 th  Annual Rodman & Renshaw Global Investment Conference, sponsored by H. C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017, at Lotte New York

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19,

Overall revenue of $3.5M is up 5% year-over-year Quell shipments of 15.6K devices are up 29% year-over-year Quell shipments of 28.7K electrode reorders are up 99% year-over-year Capital structure was simplified with 86% of outstanding warrants retired WALTHAM, Mass.

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ: NURO) today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell ® device usability by improving performance for users that maintain an active

WALTHAM, Mass. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the 10 th Annual Biotech Showcase 2018 Conference at the Hilton San Francisco Union Square on Monday,

WALTHAM, Mass. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D ., Ph.D., President and Chief Executive Officer, will participate in a panel at the Digital Health Summit at CES 2018.  The panel, “The Vicious Spiral: How Will the Opioid

WALTHAM, Mass. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported preliminary financial highlights for the fourth quarter and for the full year 2017. GAAP revenue for the fourth quarter of 2017 is estimated at approximately $4.9 million in comparison with $3.7